Structure posts early oral obesity data, delays larger readout

Structure posts early oral obesity data, delays larger readout

Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks. | Structure Therapeutics has shared an early look at the efficacy of its oral GLP-1 receptor agonist, linking the candidate to a 5% reduction in weight after four weeks.

IJMS, Free Full-Text

DNA, Free Full-Text

Regulatory Considerations for Early Clinical Development of Drugs for Diabetes, Obesity, and Cardiometabolic Disorders

Over the Past Decade, Person-First Language Was Used in Only About Half of Diabetes-Focused Articles and Fewer than 1% of Obesity Articles, Finds New Study

The physiological control of eating: signals, neurons, and networks

Ingestible Sensors and Sensing Systems for Minimally Invasive Diagnosis and Monitoring: The Next Frontier in Minimally Invasive Screening

NAD+ in COVID-19 and viral infections: Trends in Immunology

Altering the Intestinal Microbiota during a Critical Developmental Window Has Lasting Metabolic Consequences: Cell

Future cancer research priorities in the USA: a Lancet Oncology Commission - The Lancet Oncology

Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials - The Lancet

Diet and the gut microbiome: from hype to hypothesis, British Journal of Nutrition

Epigenetic regulation of aging: implications for interventions of aging and diseases

Structure Raises $300M as Oral GLP-1 Drug's Data Keep Up With Pfizer, Eli Lilly - MedCity News